Targeted Therapy (Investigational)
44 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.
Targeted Therapy (Investigational) (44)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Alisertib |
Polo-Like / Aurora Kinase Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Alisertib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Polo-Like / Aurora Kinase Inhibitor |
||||
AT7519 (CDK Inhibitor) |
Gamma-Secretase / CDK Inhibitor | Solid Tumour (Sarcoma) | ||
|
Molecule
AT7519 (CDK Inhibitor)
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour (Sarcoma)
Drug Class / Mechanism
Gamma-Secretase / CDK Inhibitor |
||||
AZD4547 (Investigational FGFR) |
FGFR Inhibitor | Solid Tumour | ||
|
Molecule
AZD4547 (Investigational FGFR)
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
||||
Barasertib |
Polo-Like / Aurora Kinase Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Barasertib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Polo-Like / Aurora Kinase Inhibitor |
||||
Bezuclastinib |
Selective KIT D816V Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Bezuclastinib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Selective KIT D816V Inhibitor |
||||
BGB-16673 (BTK Degrader) |
Targeted Protein Degrader | Hematologic | ||
|
Molecule
BGB-16673 (BTK Degrader)
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
||||
BI-847325 |
Polo-Like / Aurora Kinase Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
BI-847325
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Polo-Like / Aurora Kinase Inhibitor |
||||
BMS-986205 (Linrodostat) |
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) | Solid Tumour | ||
|
Molecule
BMS-986205 (Linrodostat)
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
||||
CFT7455 (Cereblon Degrader) |
Targeted Protein Degrader | Hematologic | ||
|
Molecule
CFT7455 (Cereblon Degrader)
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
||||
Danusertib |
Polo-Like / Aurora Kinase Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Danusertib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Polo-Like / Aurora Kinase Inhibitor |
||||
Daraxonrasib |
Pan-RAS(ON) Multi-Selective Tri-Complex Inhibitor | Solid Tumour | ||
|
Molecule
Daraxonrasib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Pan-RAS(ON) Multi-Selective Tri-Complex Inhibitor |
||||
Debio 1347 (FGFR Inhibitor) |
FGFR Inhibitor | Solid Tumour | ||
|
Molecule
Debio 1347 (FGFR Inhibitor)
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
||||
AlisertibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Polo-Like / Aurora Kinase Inhibitor |
|
AT7519 (CDK Inhibitor)Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour (Sarcoma)
Drug Class / Mechanism
Gamma-Secretase / CDK Inhibitor |
|
AZD4547 (Investigational FGFR)Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
|
BarasertibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Polo-Like / Aurora Kinase Inhibitor |
|
BezuclastinibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Selective KIT D816V Inhibitor |
|
BGB-16673 (BTK Degrader)Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
|
BI-847325Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Polo-Like / Aurora Kinase Inhibitor |
|
BMS-986205 (Linrodostat)Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
|
CFT7455 (Cereblon Degrader)Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
|
DanusertibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Polo-Like / Aurora Kinase Inhibitor |
|
DaraxonrasibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Pan-RAS(ON) Multi-Selective Tri-Complex Inhibitor |
|
Debio 1347 (FGFR Inhibitor)Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
|